Arrowhead Bets Quarterly Dosing Can Succeed Where Ionis Monthly sHTG Launch Stalled

Arrowhead Confident in Redemplo Launch Despite Ionis' Tryngolza Woes

Arrowhead Pharmaceuticals is preparing for the second-quarter launch of its drug Redemplo in severe hypertriglyceridemia (sHTG), despite the challenging market context set by competitor Ionis Pharmaceuticals. Ionis reported flat sales of just $9 million for its drug Tryngolza in the same indication, leading to a lowered annual sales guidance of $50 million and investor dismay. Arrowhead's CEO, Chris Anzalone, expressed confidence in Redemplo's differentiated profile and commercial execution, attributing Ionis' struggles to communication and commercial missteps. Redemplo, already approved for familial chylomicronemia syndrome (FCS) in November 2025, generated $6.6 million in sales in fiscal year 2026 and has been submitted to the FDA for sHTG under an accelerated review program.

• Ionis Pharmaceuticals' Tryngolza reported disappointing third-quarter sales of $9 million and a reduced annual sales guidance of $50 million for severe hypertriglyceridemia (sHTG). This performance was described by analysts as 'even worse than what were already low expectations,' creating a cautious market sentiment for new entrants in the sHTG space and highlighting potential commercial execution challenges.
• Arrowhead Pharmaceuticals remains confident in the upcoming launch of Redemplo for sHTG, with CEO Chris Anzalone asserting that Ionis' market struggles do not affect their expectations. Arrowhead believes Redemplo offers a differentiated profile and aims to avoid the 'missteps in communication' and 'commercial execution' observed with Tryngolza. The company has submitted Redemplo to the FDA, gaining entry into the Split Real Time Application Review (STAR) pilot program for a potentially faster decision.
• Redemplo has already demonstrated initial commercial success, recording $6.6 million in sales during fiscal year 2026 following its approval for familial chylomicronemia syndrome (FCS) in November 2025. While analysts acknowledge a 'tricky setup' for the sHTG launch, Jefferies estimates the drug could still achieve significant peak sales of $2.5 billion, buoyed by its early performance in FCS and Arrowhead's confidence in its market strategy.

Addressing Unmet Needs in Severe Hypertriglyceridemia

Current management of severe hypertriglyceridemia is based on lifestyle changes and, usually, drug combinations (statin and fibrate and/or omega-3 fatty acids or niacin). Despite these options, residual cardiovascular risk persists and triglyceride control remains variable, with slow response and frequent persistence.

• Modest efficacy of statins and disappointing add-on cardiovascular outcomes: Statins primarily target elevated low-density lipoprotein cholesterol levels, but have also been shown to reduce mean triglyceride levels by up to 18% (or 43% in patients with triglyceride levels≥3.1 mmol/L [≥273 mg/dL]). Results of recent outcomes trials of long-chain omega-3 fatty acids, fibrates, and niacin have been disappointing, failing to show additional reductions in adverse cardiovascular events when combined with statins, and large-scale clinical trials of fibrates have shown negative results for prevention of ASCVD. The data about the combination of fibrate therapy with statin therapy are disappointing.

• Safety, tolerability and interaction burden: Conventional fibrates have low selectivity for peroxisome proliferator-activated receptor (PPAR)α, and fibrates' clinical use causes side effects such as worsening liver function and elevating the creatinine level. Laboratory tests for liver, renal and muscle function statistically significantly elevated after starting fenofibrate co-administration, and the use of statins in the management of dyslipidemia is complicated by drug interactions with some of the components of HAART. Rosuvastatin was withdrawn in 2 patients because of myositis, and in 1 because of gastrointestinal intolerance.

• Slow, variable response with high persistence, especially with secondary causes: There was considerable variability in the number of days for the plasma TGs to decrease to <1,000 mg/dL (147.7 ± 567.3 days) and to further decrease to <500 mg/dL (136.84 ± 230.9 days). Patients with diabetes required the longest time to improve their plasma TGs (165.8 ± 305.7 days) compared to other groups, and sixty-seven patients (54%) had persistent HTG. Correcting secondary factors and optimizing lifestyle choices, including dietary modification, is important before starting drug treatment, and management is challenging as risks and benefits of treatment options need to be weighed against fetal wellbeing in pregnancy.

• Paucity of comparative evidence to guide acute management: Currently, there is paucity of studies directly comparing different modalities for hypertriglyceridemia induced acute pancreatitis, which includes plasmapheresis, insulin, heparin infusion, and hemofiltration. Dietary supplements are not subject to the same government regulatory standards for safety, efficacy, and purity as prescription drugs are, and supplements may contain variable concentrations of EPA and DHA and possibly other contaminants.

Redemplo's Differentiated Safety and Tolerability Profile

Across completed clinical studies, plozasiran (Redemplo®) demonstrated a generally favorable safety profile. In the phase 3 PALISADE trial in patients with familial chylomicronemia syndrome (FCS), plozasiran 25 mg was associated with a lower incidence of pancreatitis compared with placebo. Adverse events were primarily limited to abdominal pain, nasopharyngitis, headache, and nausea, with a low incidence of thrombocytopenia reported.

Specific safety signals included hyperglycemia observed in some patients with preexisting diabetes or prediabetes at baseline. Population pharmacodynamic modeling identified body mass index (BMI) and background triglyceride-lowering therapy as the only statistically significant covariates without clinical importance, supporting the subcutaneous 25 mg quarterly dosing (Q3M) regimen as approved for all adult FCS patients, including those with Asian ethnicity, mild-to-moderate degrees of renal impairment or a mild degree of hepatic impairment.

Compared with earlier apolipoprotein C-III-targeted antisense oligonucleotides, plozasiran offers the advantages of less frequent dosing, sustained pharmacodynamic effects, and potentially a more favorable tolerability profile based on indirect evidence. The model-estimated elimination half-life of plozasiran in the liver was 48 days, supporting quarterly dosing (Q3M) for patients' convenience, with ongoing phase 3 trials (SHASTA-3, SHASTA-4, SHASTA-5, SHASTA-10, MUIR-3 and CAPITAN) further evaluating efficacy and safety in broader populations with hypertriglyceridemia.

Navigating the Evolving Severe Hypertriglyceridemia Landscape

Severe hypertriglyceridemia (sHTG) remains defined by fasting triglycerides ≥10 mmol/L (≥885 mg/dL) with fasting chylomicronemia, encompassing rare familial chylomicronemia syndrome (FCS) due to biallelic loss-of-function variants in LPL, GPIHBP1, APOA5, APOC2, and LMF1, and the more common multifactorial chylomicronemia syndrome (MCS). Established therapies have shown inconsistent translation of triglyceride lowering into cardiovascular risk reduction. In REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial), assignment to icosapent ethyl, a highly purified eicosapentaenoic acid (EPA), resulted in a 25% reduction in nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, coronary revascularization and hospitalization for unstable angina. By contrast, the combination of EPA and docosahexaenoic acid (DHA) carboxylic fatty acids used in the STRENGTH trial (Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) failed to reduce CVD risk, and PROMINENT (Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes) also failed to demonstrate reduction in CVD events despite significant reductions (~25-35%) in triglyceride levels and despite background statin therapy. Fibrates, omega-3 fatty acids and niacin remain used to help prevent pancreatitis in patients with severe hypertriglyceridemia, with gemfibrozil reducing TG from 47.6 ± 55.7 to 9.4 ± 7.5 mmol/L (mean reduction 38.2 ± 54.5 mmol/L, P<0.001) and fenofibrate lowering TG from 45.4 ± 56.4 to 18.4 ± 13.1 mmol/L (mean difference 27.1 ± 52.0 mmol/L, P=0.001) in pediatric FCS, while pemafibrate 0.1 mg once daily reduced TG by -20.8 ± 47.6% (P < 0.01) and increased HDL-C by 3.9 ± 10.2 mg/dL (P < 0.05).

Targeted inhibition of apolipoprotein C-III (APOC3) and angiopoietin-like 3 (ANGPTL3) has reshaped trial outcomes in sHTG. Olezarsen (Tryngolza), a N-acetylgalactosamine (GalNAc)-conjugated antisense oligonucleotide that selectively inhibits hepatic ApoC-III, was approved by the Food and Drug Administration on December 19, 2024 for adults with FCS. In the Phase 3 BALANCE trial, olezarsen reduced fasting triglycerides by approximately 60% at 12 months in patients with familial chylomicronemia syndrome (FCS), with a marked decrease in pancreatitis events versus placebo, and consistent triglyceride reductions (around 50%) were also observed in moderate and severe hypertriglyceridemia. A meta-analysis of three randomized trials involving 1127 patients showed olezarsen significantly reduced mean percentage change from baseline of triglyceride levels, especially for the non-familial chylomicronemia syndrome (non-FCS) population (MD = -59.95%; 95% CI -76.00 to -43.90; P = .001), of apolipoprotein C-III levels (MD = -66.68%; 95% CI -80.86 to -52.69; P = .0006) at 6 months, with reductions in non-high-density lipoprotein cholesterol (non-HDL-C) (MD = -23.72%; 95% CI: -27.35, -20.09; P = .00001) and remnant cholesterol (MD = -55.30%; 95% CI: -62.05, -48.56; P = .00001) with an increase in LDL level, and reduced risk of acute pancreatitis (1.2% vs 8.7%; RR = 0.14; 95% CI: 0.07, 0.29; P = .00001). In SHASTA-2 (Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia), a placebo-controlled, double-blind, dose-ranging, phase 2b randomized clinical trial in adults with fasting triglyceride levels in the range of 500 to 4000 mg/dL, plozasiran induced significant dose-dependent placebo-adjusted least squares (LS)-mean reductions in triglyceride levels of -57% (95% CI, -71.9% to -42.1%; P < .001), driven by placebo-adjusted reductions in APOC3 of -77% (95% CI, -89.1% to -65.8%; P < .001) at week 24 with the highest dose, with 144 of 159 (90.6%) achieving triglyceride level of less than 500 mg/dL. In a network meta-analysis of 10 RCTs with 1,129 patients, volanesorsen 300 mg once weekly showed the most significant percent reduction in triglyceride levels (MD = -91.0%, 95% CI: (-109.2%; -72.8%); P < 0.01). Evinacumab 15 mg/kg every 4 weeks over a 12-week double-blind treatment period in cohorts with FCS with bi-allelic loss-of-function lipoprotein lipase (LPL) pathway mutations (n = 17), MCS with heterozygous loss-of-function LPL pathway mutations (n = 15), and MCS without LPL pathway mutations (n = 19) reduced triglycerides in cohort 3 by a mean (s.e.m.) of -27.1% (37.4) (95% confidence interval -71.2 to 84.6), but the prespecified primary end point was not met.

Differentiation of FCS from MCS now guides selection for these therapies. FCS compared to MCS patients were significantly younger (31.4 ± 16.7 vs. 51.0 ± 11.3 years; P =0.003), with earlier age at symptom onset (15.0 ± 15.8 vs. 37.8 ± 8.8 years; P =0.00066), lower body mass index (23.3 ± 3.1 vs. 30.7 ± 5.0 kg/m2; P =0.000016), and higher prevalence of pancreatitis events (81.8% vs. 35.2%; P=0.003), with higher ratio of triglyceride to total cholesterol, i.e. 4.18 ± 0.92 vs 1.08 ± 0.51 (P <0.0001) and lower plasma apolipoprotein B, i.e. 0.56 ± 0.15 vs 1.02 ± 0.43 g/L (P <0.0001). Heterozygosity for FCS genes contributes to 15-25% of multifactorial chylomicronemia syndrome (MCS) cases, with triglyceride phenotypes ranging from completely normal levels to severe hypertriglyceridemia, and MCS patients with heterozygous pathogenic variants had a relatively more severe clinical presentation than other MCS genetic subgroups. A high pancreatitis polygenic risk score (≥ 0.44) was associated with a 2.94-fold increase risk of acute pancreatitis (p = 0.02) among patients with MCS, rising to 9.50-fold increase risk (p = 0.001) with coexistent rare variant in TG metabolism-related genes. APOC3 inhibitors including volanesorsen, olezarsen, and plozasiran achieve up to 80% reductions in triglycerides and markedly lower AP incidence, with 8.2% of MCS patients with sustained refractory hypertriglyceridemia behaving functionally as if they have FCS, which should influence eligibility for novel therapies for severe hypertriglyceridemia.